GMP Manufacturing & Development for Advanced Cell and Gene Therapies. Located at Tel Aviv Sourasky Medical Center, I-ACT supports innovators in translating breakthrough science into clinical-grade therapies.
Who We Are
I-ACT — The Institute for Advanced Cellular Therapies
From cell-based immunotherapies to gene-edited stem cells and personalized regenerative approaches — I-ACT translates advanced therapies into GMP-compliant clinical products
I-ACT is a hospital-based, GMP-certified facility dedicated to enabling the development and clinical delivery of advanced cell and gene therapies.
Based at Tel Aviv Sourasky Medical Center, one of Israel’s leading hospitals, we specialize in helping academic investigators and biotech startups bring their therapeutic ideas to life — through high-quality development, compliant manufacturing, and clinical integration.
We are licensed by the Israeli Ministry of Health for the manufacture of gene, cell, and tissue-based therapies for human application.
Team
What We Offer
Clinical-grade production of cell and gene therapies in certified cleanroom environments.
- ISO 7 & 8 cleanroom environments
- Phase I/II clinical trial manufacturing
- Autologous and allogeneic product manufacturing
- Batch record development and quality documentation
- Support for investigator-initiated and sponsor-led trials
- Cryopreservation and controlled-rate freezing
From lab bench to bedside, Comprehensive support to transition therapies from research to clinical application.
- Process design and optimization
- Scale-up and technology transfer
- Analytical method development and validation
- Scientific consulting for preclinical-to-clinical transition
A flexible, collaborative platform for early-stage development and translational research.
- Lab space and support for biotech startups and academic groups
- Close collaboration with physicians and clinical departments
- Integrated access to hospital-based trials and patient populations
- Custom partnership models and project support
Leveraging insights from leading institutions to enhance our offerings.
- Cell expansion and manipulation for adoptive cellular therapies
- Generation of tumor vaccines using genetic or culture-mediated modification of tumor cells
- Preparation of immune cell populations for adoptive cellular therapy
- Education and training in select core technologies
Why Choose I-ACT?
Bridging Innovation and Clinical Care
- Based in a top-tier academic medical center
- Full GMP certification and cleanroom infrastructure
- In-house scientific, development and QA expertise
- Access to clinical trial infrastructure and regulatory guidance
- Proven track record in CAR-T, stem cell therapies, and novel modalities
- Ideal for startups seeking high-quality, flexible development and manufacturing partnerships
Project Highlights
While many of our projects are confidential, here are a few representative milestones:
- CAR-T for Multiple Myeloma: Manufacturing and clinical implementation of Israel’s first hospital-developed CAR-T product.
- Autologous Stem Cell Therapy for EB: Developed an in-house solution for epidermolysis bullosa (EB) following bone marrow transplantation, building on international protocols and adapting them to local capabilities.
- Emerging Collaborations: Early-stage projects underway with hospital PIs, including, virus-specific T cell therapies, iPSC-based platforms and more.
Our Facilities
Located within Ichilov Hospital, I-ACT offers direct access to:
- GMP Cleanroom Suites (ISO 7 & 8)
- Development & QC Laboratories
- Cryopreservation and cell banking
- Seamless integration with hospital logistics and data systems
Contact & Collaborate
HOW WE ACT
